Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Chrysanthi MantsiouThomas KaragiannisPanagiota KakotrichiKonstantinos MalandrisIoannis AvgerinosAris LiakosApostolos TsapasApostolos TsapasPublished in: Diabetes, obesity & metabolism (2020)
GLP-1RA/SGLT2i combination therapy seems to reduce HbA1c , body weight and systolic blood pressure without increasing the risk of severe hypoglycaemia compared with either GLP-1RA or SGLT2i. No conclusions can be made regarding long-term effectiveness or the effect on cardiovascular outcomes.
Keyphrases
- combination therapy
- body weight
- blood pressure
- type diabetes
- rheumatoid arthritis
- disease activity
- hypertensive patients
- randomized controlled trial
- heart rate
- heart failure
- ankylosing spondylitis
- systematic review
- glycemic control
- left ventricular
- cardiovascular disease
- early onset
- interstitial lung disease
- insulin resistance
- systemic sclerosis
- idiopathic pulmonary fibrosis